Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research

The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.

Sanofi Plans To Discontinue Diabetes And Cardiovascular Disease Research.

Sanofi – a world leader in diabetes drug development – is exiting diabetes research. The announcement on 9 December, one day ahead of the French company's capital markets day presentation, is not surprising given the commercial challenges Sanofi has faced in the therapy area in recent years, but it's not insignificant either.

The decision highlights the increasingly challenging dynamics in developing and marketing drugs for diabetes, where pressure on prices has grown and newer launches haven't necessarily delivered the same level of advancement seen in other therapeutic areas like cancer and rare

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Multiple Launches Help Lilly’s Japan Growth

15 May 2025

• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

14 May 2025

• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.